TD Securities Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by stock analysts at TD Securities from a “buy” rating to a “hold” rating in a research report issued on Tuesday,BayStreet.CA reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday.

Milestone Pharmaceuticals Stock Down 4.8 %

MIST traded down $0.04 during trading hours on Tuesday, reaching $0.76. 3,585,980 shares of the stock traded hands, compared to its average volume of 698,361. Milestone Pharmaceuticals has a fifty-two week low of $0.72 and a fifty-two week high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The company has a market cap of $40.66 million, a price-to-earnings ratio of -0.94 and a beta of 1.83. The firm’s fifty day simple moving average is $1.97 and its two-hundred day simple moving average is $1.83.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp grew its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after buying an additional 10,000 shares during the last quarter. National Bank of Canada FI grew its holdings in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Cubist Systematic Strategies LLC bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $73,000. Finally, XTX Topco Ltd acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at approximately $80,000. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.